ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,718.57
      0.28%
      US Tech 100
      19,312.80
      0.08%
      Dow Jones
      42,124.65
      0.15%
      Brent Oil
      74.10
      0.50%
      Bitcoin
      63,196.12
      -0.21%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Delcath Systems Inc (DCTH) Quote

      Delcath Systems Inc

      Delcath Systems Inc (DCTH)

      NASDAQ
      8.74
      -0.26
      (-2.89%)
      Closed September 24 4:00PM
      Delayed by 15 minutes
      8.85
      0.11
      (1.26%)
      After Hours: 7:53PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      8.85
      Bid
      8.63
      Ask
      10.03
      Volume
      283,868
      8.72 Day's Range 9.16
      2.25 52 Week Range 11.745
      Market Cap
      247.796M
      Previous Close
      9.00
      Open
      9.12
      Last Trade
      5
      @
      8.85
      Last Trade Time
      Financial Volume
      $ 2,512,071
      VWAP
      8.8494
      Average Volume (3m)
      269,094
      Shares Outstanding
      27,999,522
      Dividend Yield
      -
      PE Ratio
      -5.13
      Earnings Per Share (EPS)
      -1.7
      Revenue
      2.07M
      Net Profit
      -47.68M

      About Delcath Systems Inc

      Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy... Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Show more

      Sector
      Surgical,med Instr,apparatus
      Industry
      Surgical,med Instr,apparatus
      Website
      www.delcath.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Delcath Systems Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DCTH. The last closing price for Delcath Systems was $9. Over the last year, Delcath Systems shares have traded in a share price range of $ 2.25 to $ 11.745.

      Delcath Systems currently has 27,999,522 shares outstanding. The market capitalization of Delcath Systems is $252 million. Delcath Systems has a price to earnings ratio (PE ratio) of -5.13.

      Ask ADVFN Intelligence (AI)

      Delcath Systems (DCTH) Options Flow Summary

      DCTH Options Flow

      Overall Flow

      Bullish

      Net Premium

      31k

      Calls / Puts

      100.00%

      Buys / Sells

      100.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      DCTH Latest News

      More News

      Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...

      September 20 2024
      Business Wire

      Form POS AM - Post-Effective amendments for registration statement

      September 18 2024
      Edgar (US Regulatory)

      Form POS AM - Post-Effective amendments for registration statement

      September 18 2024
      Edgar (US Regulatory)

      Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

      Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS...

      September 16 2024
      Business Wire

      Form 8-K - Current report

      August 29 2024
      Edgar (US Regulatory)

      Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

      Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the...

      August 28 2024
      Business Wire

      Form 8-K - Current report

      August 28 2024
      Edgar (US Regulatory)

      Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

      Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the...

      August 27 2024
      Business Wire

      Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

      Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication...

      August 26 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.7-7.329842931949.559.7868.732598799.16381959CS
      40.749.124537607898.1111.7458.08537242810.08914583CS
      120.536.370192307698.3211.7457.17012690948.97363311CS
      264.1889.50749464674.6711.7454.262781137.54972548CS
      524.74115.3284671534.1111.7452.252798705.54445353CS
      156-0.42-4.530744336579.2714.952.253054985.54998761CS
      2608.75018758.858858860.099925.180.09992409986.67933288CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      LASELaser Photonics Corporation
      $ 18.8671
      (81.24%)
      		13.54M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M
      NVVENuvve Holding Corporation
      $ 6.68
      (70.41%)
      		31.34M
      UXINUxin Ltd
      $ 2.42
      (52.68%)
      		18.24M
      ELABElevai Labs Inc
      $ 0.10545
      (-62.34%)
      		23.66M
      ADTXAditxt Inc
      $ 0.262
      (-31.52%)
      		3.17M
      FRGTFreight Technologies Inc
      $ 0.081
      (-28.82%)
      		26.36M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.23
      (-27.60%)
      		113.78k
      STSSSharps Technology Inc
      $ 0.1722
      (-27.06%)
      		2.28M
      XPONExpion360 Inc
      $ 0.1144
      (34.91%)
      		432.21M
      NVDANVIDIA Corporation
      $ 116.26
      (0.22%)
      		206.23M
      INTCIntel Corporation
      $ 22.56
      (3.30%)
      		184.44M
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M

      DCTH Discussion

      View Posts
      Filterthenoise Filterthenoise 3 months ago
      Straight 🔥 $DCTH
      👍️0
      Monksdream Monksdream 3 months ago
      DCTH under $10
      👍️0
      Filterthenoise Filterthenoise 4 months ago
      $DCTH strong
      👍️0
      Monksdream Monksdream 6 months ago
      DCTH 10Q due 3/26
      👍️0
      Filterthenoise Filterthenoise 8 months ago
      $DCTH
      👍️0
      Filterthenoise Filterthenoise 10 months ago
      Lets go $DCTH
      👍️0
      green maschine green maschine 1 year ago
      6 now. That was quick.
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      5.80 HI :0)
      👍️0
      green maschine green maschine 1 year ago
      The 5 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 18.00, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a +216.62% increase from the last price of 5.69.
      👍️0
      dande1990 dande1990 1 year ago
      H.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)

      TipRanks

       Aug. 15, 2023, 09:35 AM

      In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems (DCTH – Research Report), with a price target of $18.00. The company’s shares opened today at $5.84.
      👍️0
      dande1990 dande1990 1 year ago
      HC Wainwright & Co. Maintains Delcath Systems (DCTH) Buy Recommendation

      Story by George Maybach • 14h

      ?

      Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
      Analyst Price Forecast Suggests 436.15% Upside
      As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 436.15% from its latest reported closing price of 3.12.

      👍️0
      TheFinalCD TheFinalCD 1 year ago
      5.13 LO :/


      SO FAR
      👍️0
      green maschine green maschine 1 year ago
      Hope you get that back working soon. I use TD Ameritrade and so far haven't had any problems with their system.
      👍️0
      dande1990 dande1990 1 year ago
      No... On my app and my laptop I have a message saying they are unable to at the moment

      $DCTH
      👍️0
      green maschine green maschine 1 year ago
      Wow, bummer. Did they say why?
      👍️0
      dande1990 dande1990 1 year ago
      Fidelity is down. Cant make trades at all.

      $DCTH
      👍️0
      green maschine green maschine 1 year ago
      Awesome! I need to get my correct my sleeping habits - kicking myself today.
      👍️0
      dande1990 dande1990 1 year ago
      Ive been able to do 5.01 to 5.77 and 5.55 to 7.25. In again at 6.33.
      👍️0
      green maschine green maschine 1 year ago
      Nice move CD. Still climbing. $$DCTH$$
      👍️0
      green maschine green maschine 1 year ago
      I'm in at 5.43, went back to bed and missed the flip today. Oh well might see 10 by EOW.
      👍️0
      dande1990 dande1990 1 year ago
      This board needs some life!! Lets go $DCTH
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      round ii

      filled as low as 6.46 on that DIP

      $DCTH
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      $7!!!!!!!!!!!!!!


      SOLD SOME 6.95 AFTER 7 COULDNT BREAK HARD
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      6.70 LG!!!!!!
      👍️0
      SriMaharaj SriMaharaj 1 year ago
      Told you guys. Get in now before it's too late.
      👍️0
      SriMaharaj SriMaharaj 1 year ago
      Wait until it cross $6. You will see $10 today or tomorrow.
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      6.50 WAS A NICE POP OFF MY 5.55 ENTRY
      👍️0
      green maschine green maschine 1 year ago
      Yeah there's resistance at that level, but I believe it'll break through today. Too much buying pressure here. FDA approval is huge news.
      👍️0
      Filterthenoise Filterthenoise 1 year ago
      BOOM $DCTH
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      6.24 SO FAR BUT THEY QUICKLY SOLD IT OFF TO 5.34

      DCTH
      👍️0
      Monksdream Monksdream 1 year ago
      Early Barchart Top 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      green maschine green maschine 1 year ago
      Good morning. I wonder how high this flies today.
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      https://finviz.com/quote.ashx?t=DCTH&p=d

      $DCTH 🚨 Approved

      Finally after years of try.

      Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma. pic.twitter.com/ZCBQZXbgzE— Ripster🪙📈📉 (@ripster47) August 15, 2023
      👍️0
      green maschine green maschine 1 year ago
      Where is everybody?
      👍️0
      Carlito78 Carlito78 1 year ago
      What ever happened to SamnotSamuel?
      👍️0
      harvest1 harvest1 1 year ago
      Wow stock is down 2 weeks before PDUFA date. Hard to imagine this wont be approved this time with no adcom. Not sure why there arent more buyers. Hopefully there is a pop on approval and they have a quick launch and revenue ramp.
      👍️0
      Filterthenoise Filterthenoise 1 year ago
      Finally! Go $DCTH
      👍️0
      Jmma Jmma 1 year ago
      Finally looks promising for real. Had shares few years ago and got chewed up and spit out . Reverse splits wiped out a lot of investors. Looks like they turned the corner and could become the investment everyone hoped for awhile back. Good luck to those holding.
      👍️0
      Filterthenoise Filterthenoise 2 years ago
      No one loving the start of the run?
      👍️0
      Filterthenoise Filterthenoise 2 years ago
      Next leg time LFG $DCTH!!
      👍️0
      Filterthenoise Filterthenoise 2 years ago
      $DCTH... LFG!
      👍️0
      Filterthenoise Filterthenoise 2 years ago
      Let's GO!

      $DCTH
      👍️0
      Filterthenoise Filterthenoise 2 years ago
      Another run at it coming

      GLTA
      👍️0
      harvest1 harvest1 2 years ago
      A new corporate presentation was posted to the company's website with alot of updated information.
      https://delcath.com/investors/events-presentations/

      This company has been left for dead by the market but I think the stock could recover strongly next year after approval if revenues begin to roll in. I would be interested to hear others thoughts on catalysts and stock price targets. I think at least a $100 million market cap should be expected on approval. Longer term at least $250 million market cap when revenues are material. Starting 3 new trials in 2023 will be positive as well. There appears to be little interest or attention for the company now but hopefully that changes after approval. My biggest fear is that they will have to dilute more at these awful rock bottom prices.
      👍️0
      Filterthenoise Filterthenoise 2 years ago
      Here we go...
      👍️0
      nealhugh nealhugh 2 years ago
      just waiting.........................................................................
      👍️0
      nealhugh nealhugh 2 years ago
      yup--- good chat with GA... TY. Neal
      👍️0
      nealhugh nealhugh 3 years ago
      FDA submission Summer/Fall 2022
      FDA approval possible within 6 mos of submission

      Fund raise? when?

      Stock price lousy so wait for the fund raise?

      All results on trials and use are good!

      TY, Neal
      👍️0
      nealhugh nealhugh 3 years ago
      https://ih.advfn.com/p.php?pid=nmona&article=87441339
      👍️0
      nealhugh nealhugh 3 years ago
      Yeah--- I had Covid so I have been delayed!!! :)
      👍️0

      Your Recent History

      NASDAQ
      DCTH
      Delcath Systems
      Delayed Upgrade Clock